SCHEMBL28536153

SCHEMBL28536153

Oc1ccc(-c2n[c]c[nH]2)cc1O

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
APP P05067 4/20 0.46
QDPR P09417 1/20 0.41
ALOX5 P09917 3/20 0.41
SNCA P37840 4/20 0.40
GUSB P08236 2/20 0.39
GAA P10253 2/20 0.39
MGAM O43451 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
MAPT P10636 2/20 0.39
IDO1 P14902 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
HPGD P15428 1/20 0.38
RECQL P46063 1/20 0.38
ESR2 Q92731 1/20 0.38
DYRK1A Q13627 1/20 0.36
GRK6 P43250 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4049587 0.79 ALDH1A1 (0.41) GUSBGAAMGAMSIMGAM2
SCHEMBL4041568 0.76 HSD17B1 (0.47) GAAMGAMSIMGAM2MAPT
SCHEMBL6002502 0.74 AHR (0.46) GAAMAPTIDO1KDM4EALDH1A1
SCHEMBL28536156 0.71 NISCH (0.47) MAPTALDH1A1
SCHEMBL28535250 0.70 KDM4E (0.50) ALOX5GUSBGAAKDM4EALDH1A1
SCHEMBL29142674 0.70 NPC1 (0.50) APPGUSBGAA
SCHEMBL29142667 0.70 BRD4 (0.43) APPKDM4EALDH1A1POLBHPGD
SCHEMBL403894 0.70 MTOR (0.43) GAAMAPTIDO1KDM4EALDH1A1
SCHEMBL10057826 0.70 APP (0.56) APPQDPRALOX5SNCAGUSB
SCHEMBL2650383 0.69 IDO1 (0.49) GAAMGAMSIMGAM2IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112512522-A Compounds for the treatment of triple negative breast and ovarian cancer 田纳西大学研究基金会 2021-03-16 CN disclosed
CN-112437664-A Compounds for the treatment of pancreatic cancer 田纳西大学研究基金会 2021-03-02 CN disclosed